Cardiorenal syndrome: Pathophysiology and potential targets for clinical management

Nature Reviews Nephrology

Volumn 9, Issue 2, 2013, Pages 99-111

  Hatamizadeh, Parta ^a   Fonarow, Gregg C ^b   Budoff, Matthew J ^c   Darabian, Sirous ^c   Kovesdy, Csaba P ^d   Kalantar Zadeh, Kamyar ^e  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ARGIPRESSIN; BRAIN NATRIURETIC PEPTIDE; FIBROBLAST GROWTH FACTOR 23; HEPCIDIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ABDOMINAL PRESSURE; ATHEROSCLEROSIS; AUTONOMIC NERVOUS SYSTEM; BLOOD VESSEL PERMEABILITY; CACHEXIA; CARDIORENAL SYNDROME; DIETARY INTAKE; DISEASE CLASSIFICATION; ENDOTHELIAL DYSFUNCTION; EXERCISE; GLOMERULUS FILTRATION RATE; HEALTH CARE QUALITY; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART TRANSPLANTATION; HUMAN; IRON ABSORPTION; IRON METABOLISM; IRON THERAPY; KIDNEY FAILURE; KIDNEY FUNCTION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MUSCLE ATROPHY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SHEAR STRESS; SODIUM ABSORPTION; UREMIA; VENTRICULAR ASSIST DEVICE; VITAMIN D DEFICIENCY;

CARDIO-RENAL SYNDROME; HEART; HUMANS; KIDNEY; RISK FACTORS;

EID: 84873158073     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2012.279     Document Type: Review

References (150)

1. NHLBI Working Group. Cardio-renal connections in heart failure and cardiovascular disease. National Heart, Lung, and Blood Institute website [online], http://www.nhlbi.nih.gov/meetings/workshops/cardiorenal-hf-hd.htm (2004).
2. Bock, J. S. & Gottlieb, S. S. Cardiorenal syndrome: new perspectives. Circulation 121, 2592-2600 (2010).
3. Dries, D. L., Exner, D. V., Domanski, M. J., Greenberg, B. & Stevenson, L. W. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J. Am. Coll. Cardiol. 35, 681-689 (2000).
4. Hillege, H. L. et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 113, 671-678 (2006).
5. Mann, J. F., Gerstein, H. C, Pogue, J., Bosch, J. & Yusuf, S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial. Ann. Intern. Med. 134, 629-636 (2001).
6. Smith, G. L. et al. Renal impairment and outcomes in heart failure: Systematic review and meta-analysis. J. Am. Coll. Cardiol. 47, 1987-1996 (2006).
7. Centers for Disease Control and Prevention. National Chronic Kidney Disease Fact Sheet [online], http://www.cdc.gov/diabetes/pubs/pdf/kidney- Factsheet.pdf (2010).
8. Roger, V. L. et al. Heart disease and stroke statistics - 2011 update: A report from the American Heart Association. Circulation 123, e18-e209 (2011).
9. Manjunath, G. et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J. Am. Coll. Cardiol. 41, 47-55 (2003).
10. Shastri, S. et al. Chronic kidney disease in octogenarians. Clin. J. Am. Soc. Nephrol. 6, 1410-1417 (2011).
11. Shlipak, M. G. et al. Rapid decline of kidney function increases cardiovascular risk in the elderly. J. Am. Soc. Nephrol. 20, 2625-2630 (2009).
12. Adams, K. F. J. et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am. Heart J. 149, 209-216 (2005).
13. Liang, K. V., Williams, A. W., Greene, E. L. & Redfield, M. M. Acute decompensated heart failure and the cardiorenal syndrome. Crit. Care Med. 36 (1 Suppl.), S75-S88 (2008).
14. Ronco, C., Haapio, M., House, A. A., Anavekar, N. & Bellomo, R. Cardiorenal syndrome. J. Am. Coll. Cardiol. 52, 1527-1539 (2008).
15. Correa de Sa, D. D. et al. Progression of preclinical diastolic dysfunction to the development of symptoms. Heart 96, 528-532 (2010).
16. Bradley, S. E. & Bradley, G. P. The effect of increased intra-abdominal pressure on renal function in man. J. Clin. Invest. 26, 1010-1015 (1947).
17. Winton, F. R. The influence of venous pressure on the isolated mammalian kidney. J. Physiol. 72, 49-61 (1931).
18. Firth J. D., Raine, A. E. & Ledingham, J. G. Raised venous pressure: A direct cause of renal sodium retention in oedema? Lancet 1, 1033-1035 (1988).
19. Maeder, M. T., Holst, D. P. & Kaye, D. M. Tricuspid regurgitation contributes to renal dysfunction in patients with heart failure. J. Card. Fail. 14, 824-830 (2008).
20. Mullens, W. et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J. Am. Coll. Cardiol. 53, 589-596 (2009).
21. Mohmand, H. & Goldfarb, S. Renal dysfunction associated with intra-abdominal hypertension and the abdominal compartment syndrome. J. Am. Soc. Nephrol. 22, 615-621 (2011).
22. Mullens, W. et al. Elevated intra-abdominal pressure in acute decompensated heart failure: A potential contributor to worsening renal function? J. Am. Coll. Cardiol. 51, 300-306 (2008).
23. Bristow, M. R. Treatment of chronic heart failure with ß adrenergic receptor antagonists: A convergence of receptor pharmacology and clinical cardiology. Circ. Res. 109, 1176-1194 (2011).
24. Bristow, M. R. et al. Decreased catecholamine sensitivity and beta adrenergic receptor density in failing human hearts. N. Engl. J. Med. 307, 205-211 (1982).
25. Bristow, M. R. et al. Beta 1 and beta 2 adrenergic receptor subpopulations in nonfailing and failing human ventricular myocardium: Coupling of both receptor subtypes to muscle contraction and selective beta 1 receptor down-regulation in heart failure. Circ. Res. 59, 297-309 (1986).
26. Bristow, M. R. et al. Reduced beta 1 receptor messenger RNA abundance in the failing human heart. J. Clin. Invest. 92, 2737-2745 (1993).
27. Esler, M. D. et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN 2 Trial): A randomised controlled trial. Lancet 376, 1903-1909 (2010).
28. Remuzzi, G., Perico, N., Macia, M. & Ruggenenti, P. The role of renin angiotensin aldosterone system in the progression of chronic kidney disease. Kidney Int. Suppl. 99, S57-S65 (2005).
29. Ruiz-Ortega, M. et al. Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int. Suppl. 82, S12-S22 (2002).
30. Jaisser, F., Swynghedauw, B. & Delcayre, C. The mineralocorticoid receptor in heart: different effects in different cells. Hypertension 57, 679-680 (2011).
31. Lother, A. et al. Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function. Hypertension 57, 746-754 (2011).
32. Goldsmith, S. R., Francis, G. S., Cowley, A. W., Levine, T. B. & Cohn, J. N. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J. Am. Coll. Cardiol. 1, 1385-1390 (1983).
33. Vallon, V., Miracle, C. & Thomson, S. Adenosine and kidney function: Potential implications in patients with heart failure. Eur. J. Heart Fail. 10, 176-187 (2008).
34. Vallon, V., Mühlbauer, B. & Osswald, H. Adenosine and kidney function. Physiol. Rev. 86, 901-940 (2006).
35. Funaya, H. et al. Plasma adenosine levels increase in patients with chronic heart failure. Circulation 95, 1363-1365 (1997).
36. Griendling, K. K., Minieri, C. A., Ollerenshaw, J. D. & Alexander, R. W. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ. Res. 74, 1141-1148 (1994).
37. Heymes, C. et al. Increased myocardial NADPH oxidase activity in human heart failure. J. Am. Coll. Cardiol. 41, 2164-2171 (2003).
38. Perianayagam, M. C. et al. NADPH oxidase p22phox and catalase gene variants are associated with biomarkers of oxidative stress and adverse outcomes in acute renal failure. J. Am. Soc. Nephrol. 18, 255-263 (2007).
39. Vaziri, N. D., Dicus, M., Ho, N. D., Boroujerdi-Rad, L. & Sindhu, R. K. Oxidative stress and dysregulation of superoxide dismutase and NADPH oxidase in renal insufficiency. Kidney Int. 63, 179-185 (2003).
40. Young, B. & Zaritsky, J. Hepcidin for clinicians. Clin. J. Am. Soc. Nephrol. 4, 1384-1387 (2009).
41. Kanai, A. J. et al. Shear stress induces ATP-independent transient nitric oxide release from vascular endothelial cells, measured directly with a porphyrinic microsensor. Circ. Res. 77, 284-293 (1995).
42. Pan, S. Molecular mechanisms responsible for the atheroprotective effects of laminar shear stress. Antioxid. Redox Signal. 11, 1669-1682 (2009).
43. Mendes Ribeiro, A. C., Brunini, T. M., Ellory, J. C. & Mann, G. E. Abnormalities in L arginine transport and nitric oxide biosynthesis in chronic renal and heart failure. Cardiovasc. Res. 49, 697-712 (2001).
44. Verbeke, F. H. et al. Flow-mediated vasodilation in end-stage renal disease. Clin. J. Am. Soc. Nephrol. 6, 2009-2015 (2011).
45. Ontkean, M., Gay, R. & Greenberg, B. Diminished endothelium-derived relaxing factor activity in an experimental model of chronic heart failure. Circ. Res. 69, 1088-1096 (1991).
46. Buga, G. M., Gold, M. E., Fukuto, J. M. & Ignarro, L. J. Shear stress-induced release of nitric oxide from endothelial cells grown on beads. Hypertension 17, 187-193 (1991).
47. Cook, J. P., Rossitch, E., Andon, N. A., Loscalzo, L. & Dazu, V. J. Flow activates an endothelial potassium channel to release an endogenous nitrovasodilator. J. Clin. Invest. 88, 1663-1671 (1991).
48. Ferrari, R., Bachetti, T., Agnoletti, L., Comini, L. & Curello, S. Endothelial function and dysfunction in heart failure. Eur. Heart J. 19 (Suppl. G), G41-G47 (1998).
49. Giannattasio, C., Piperno, A., Failla, M., Vergani, A. & Mancia, G. Effects of hematocrit changes on flow-mediated and metabolic vasodilation in humans. Hypertension 40, 74-77 (2002).
50. Francis, G. S. TNF-alpha and heart failure. The difference between proof of principle and hypothesis testing. Circulation 99, 3213-3214 (1999).
51. Levine, B., Kalman, J., Mayer, L., Fillit, H. M. & Packer, M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N. Engl. J. Med. 323, 236-241 (1990).
52. Stenvinkel, P. et al. IL 10, IL 6, and TNF-alpha: Central factors in the altered cytokine network of uremia - the good, the bad, and the ugly. Kidney Int. 67, 1216-1233 (2005).
53. Sarnak, M. J. et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108, 2154-2169 (2003).
54. Greco, B. A. & Breyer, J. A. Atherosclerotic ischemic renal disease. Am. J. Kidney Dis. 29, 167-187 (1997).
55. Karalliedde, J. & Viberti, G. Proteinuria in diabetes: bystander or pathway to cardiorenal disease? J. Am. Soc. Nephrol. 21, 2020-2027 (2010).
56. de Zeeuw, D. et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110, 921-927 (2004).
57. Ezekowitz, J. A., McAlister, F. A. & Armstrong, P. W. Anemia is common in heart failure and is associated with poor outcomes: Insights from a cohort of 12 065 patients with new-onset heart failure. Circulation 107, 223-225 (2003).
58. Horwich, T. B., Fonarow, G. C., Hamilton, M. A., MacLellan, W. R. & Borenstein, J. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J. Am. Coll. Cardiol. 39, 1780-1786 (2002).
59. Okonko, D. O., Mandal, A. K., Missouris, C. G. & Poole-Wilson, P. A. Disordered iron homeostasis in chronic heart failure: Prevalence, predictors, and relation to anemia, exercise capacity, and survival. J. Am. Coll. Cardiol. 58, 1241-1251 (2011).
60. Naito, Y. et al. Impaired expression of duodenal iron transporters in Dahl salt-sensitive heart failure rats. J. Hypertens. 29, 741-748 (2011).
61. Divakaran, V. et al. Hepcidin in anemia of chronic heart failure. Am. J. Hematol. 86, 107-109 (2011).
62. Anand, I. S., Chandrashekhar, Y., Ferrari, R., Poole-Wilson, P. A. & Harris, P. C. Pathogenesis of oedema in chronic severe anaemia: Studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones. Br. Heart J. 70, 357-362 (1993).
63. Sandgren, P. E. et al. Anemia and new-onset congestive heart failure in the general Medicare population. J. Card. Fail. 11, 99-105 (2005).
64. Anker, S. D. & Sharma, R. The syndrome of cardiac cachexia. Int. J. Cardiol. 85, 51-66 (2002).
65. Kalantar-Zadeh, K. et al. Recent advances in understanding the malnutrition inflammation cachexia syndrome in chronic kidney disease patients: what is next? Semin. Dial. 18, 365-369 (2005).
66. Sukhanov, S. et al. Angiotensin II, oxidative stress and skeletal muscle wasting. Am. J. Med. Sci. 342, 143-147 (2011).
67. Tan, B. H. & Fearon, K. C. Cachexia: Prevalence and impact in medicine. Curr. Opin. Clin. Nutr. Metab. Care 11, 400-407 (2008).
68. Kalantar-Zadeh, K., Anker, S. D., Horwich, T. B. & Fonarow, G. C. Nutritional and anti-inflammatory interventions in chronic heart failure. Am. J. Cardiol. 101, 89EY103E (2008).
69. Kalantar-Zadeh, K. et al. Diets and enteral supplements for improving outcomes in chronic kidney disease. Nat. Rev. Nephrol. 7, 369-384 (2011).
70. Mak, R. H. et al. Wasting in chronic kidney disease. J. Cachexia Sarcopenia Muscle 2, 9-25 (2011).
71. Pilz, S. et al. Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. J. Clin. Endocrinol. Metab. 93, 3927-3935 (2008).
72. Zittermann, A. et al. Low vitamin D status: A contributing factor in the pathogenesis of congestive heart failure? J. Am. Coll. Cardiol. 41, 105-112 (2003).
73. Lind, L., Wengle, B. & Ljunghall, S. Blood pressure is lowered by vitamin D (alphacalcidol) during long-term treatment of patients with intermittent hypercalcaemia. A double-blind, placebo-controlled study. Acta Med. Scand. 222, 423-427 (1987).
74. Pfeifer, M., Begerow, B., Minne, H. W., Nachtigall, D. & Hansen, C. Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J. Clin. Endocrinol. Metab. 86, 1633-1637 (2001).
75. Park, C. W. et al. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am. J. Kidney Dis. 33, 73-81 (1999).
76. Chen, S. et al. Cardiomyocyte-specific deletion of the vitamin D receptor gene results in cardiac hypertrophy. Circulation 124, 1838-1847 (2011).
77. Jüppner, H. Phosphate and FGF 23. Kidney Int. Suppl. 79, S24-S27 (2011).
78. Faul, C. et al. FGF23 induces left ventricular hypertrophy. J. Clin. Invest. 121, 4393-4408 (2011).
79. Plischke, M. et al. Inorganic phosphate and FGF 23 predict outcome in stable systolic heart failure. Eur. J. Clin. Invest. 42, 649-656 (2012).
80. Shalhoub, V. et al. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J. Clin. Invest. 122, 2543-2553 (2012).
81. McCullough, P. A., El-Ghoroury, M. & Yamasaki, H. Early detection of acute kidney injury with neutrophil gelatinase-associated lipocalin. J. Am. Coll. Cardiol. 57, 1762-1764 (2011).
82. Ronco, C. et al. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur. Heart J. 31, 703-711 (2010).
83. Haase, M. et al. The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute kidney injury: A multicenter pooled analysis of prospective studies. J. Am. Coll. Cardiol. 57, 1752-1761 (2011).
84. Tallaj, J. A., Singla, I. & Bourge, R. C. Implantable hemodynamic monitors. Cardiol. Clin. 29, 289-299 (2011).
85. deFilippi, C. R., Seliger, S. L., Maynard, S. & Christenson, R. H. Impact of renal disease on natriuretic peptide testing for diagnosing decompensated heart failure and predicting mortality. Clin. Chem. 53, 1511-1519 (2007).
86. Elkayam, U., Hatamizadeh, P. & Janmohamed, M. The challenge of correcting volume overload in hospitalized patients with decompensated heart failure. J. Am. Coll. Cardiol. 49, 684-686 (2007).
87. Gupta, S. & Neyses, L. Diuretic usage in heart failure: A continuing conundrum in 2005. Eur. Heart J. 26, 644-649 (2005).
88. Konstam, M. A. et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial. JAMA 297, 1319-1331 (2007).
89. Felker, G. M. et al. Diuretic strategies in patients with acute decompensated heart failure. N. Engl. J. Med. 364, 797-805 (2011).
90. Jenkins, P. G. Diuretic strategies in patients with acute heart failure. N. Engl. J. Med. 364, 2066 (2011).
91. Dalzell, J. R. Diuretic strategies in patients with acute heart failure. N. Engl. J. Med. 364, 2066-2067 (2011).
92. Costanzo, M. R. et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J. Am. Coll. Cardiol. 49, 675-683 (2007).
93. Bart, B. A. et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1210357.
94. Tang, W. H. Reconsidering ultrafiltration in the acute cardiorenal syndrome. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMe1212881.
95. Khalifeh, N., Vychytil, A. & Horl, W. H. The role of peritoneal dialysis in the management of treatment-resistant congestive heart failure: A European perspective. Kidney Int. Suppl. 103, S72-S75 (2006).
96. Krishnan, A. & Oreopoulos, D. G. Peritoneal dialysis in congestive heart failure. Adv. Perit. Dial. 23, 82-89 (2007).
97. Mehrotra, R. & Kathuria, P. Place of peritoneal dialysis in the management of treatment-resistant congestive heart failure. Kidney Int. Suppl. 103, S67-S71 (2006).
98. Sanchez, J. E. et al. Efficacy of peritoneal ultrafiltration in the treatment of refractory congestive heart failure. Nephrol. Dial. Transplant. 25, 605-610 (2010).
99. Uchino, S. et al. Super high flux hemofiltration: A new technique for cytokine removal. Intensive Care Med. 28, 651-655 (2002).
100. Churchill, D. N. et al. Effect of high-flux hemodialysis on cardiac structure and function among patients with end-stage renal failure. Nephron 65, 573-577 (1993).
101. Elkayam, U. et al. Vasodilators. In Congestive Heart Failure 3rd edn (eds Hosenpud, J. D. & Greenberg, B. H.) 489-509 (Lippincott Williams & Wilkins, Philadelphia, 2006).
102. Elkayam, U., Janmohamed, M., Habib, M. & Hatamizadeh, P. Vasodilators in the management of acute heart failure. Crit. Care Med. 36, S95-S105 (2008).
103. Tavares, M., Rezlan, E., Vostroknoutova, I., Khouadja, H. & Mebazaa, A. New pharmacologic therapies for acute heart failure. Crit. Care Med. 36 (1 Suppl.), S112-S120 (2008).
104. McMurray, J. J. et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: The VERITAS randomized controlled trials. JAMA 298, 2009-2019 (2007).
105. Anand, I. et al. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet 364, 347-354 (2004).
106. Petersen, J. W. & Felker, G. M. Inotropes in the management of acute heart failure. Crit. Care Med. 36 (1 Suppl.), S106-S111 (2008).
107. Kass, D. A. & Solaro, R. J. Mechanisms and use of calcium-sensitizing agents in the failing heart. Circulation 113, 305-315 (2006).
108. Givertz, M. M., Andreou, C., Conrad, C. H. & Colucci, W. S. Direct myocardial effects of levosimendan in humans with left ventricular dysfunction: Alteration of force-frequency and relaxation-frequency relationships. Circulation 115, 1218-1224 (2007).
109. Hajjar, R. J. & Gwathmey, J. K. Calcium-sensitizing inotropic agents in the treatment of heart failure: A critical view. Cardiovasc. Drugs Ther. 5, 961-965 (1991).
110. Sackner-Bernstein, J. D., Kowalski, M., Fox, M. & Aaronson, K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: A pooled analysis of randomized controlled trials. JAMA 293, 1900-1905 (2005).
111. Arora, R. R., Venkatesh, P. K. & Molnar, J. Short and long-term mortality with nesiritide. Am. Heart J. 152, 1084-1090 (2006).
112. O'Connor, C. M. et al. Effect of nesiritide in patients with acute decompensated heart failure. N. Engl. J. Med. 365, 32-43 (2011).
113. Witteles, R. M. et al. Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction a randomized, double-blind, placebo-controlled clinical trial. J. Am. Coll. Cardiol. 50, 1835-1840 (2007).
114. Elkayam, U. et al. Impact of acute serum creatinine elevation in patients treated with nesiritide. Clin. Cardiol. 32, 215-219 (2009).
115. McDonald, R. H., Goldberg, L. I., McNay, J. L. & Tuttle, E. P. Effects of dopamine in man: Augmentation of sodium excretion, glomerular filtration rate, and renal plasma flow. J. Clin. Invest. 43, 1116-1124 (1964).
116. Elkayam, U., Ng, T. M., Hatamizadeh, P., Janmohamed, M. & Mehra, A. Renal vasodilatory action of dopamine in patients with heart failure: magnitude of effect and site of action. Circulation 117, 200-205 (2008).
117. Butler, J. et al. Relationship between renal function and left ventricular assist device use. Ann. Thorac. Surg. 81, 1745-1751 (2006).
118. Sandner, S. E. et al. Renal function and outcome after continuous flow left ventricular assist device implantation. Ann. Thorac. Surg. 87, 1072-1078 (2009).
119. Santambrogio, L. et al. Right ventricular failure after left ventricular assist device insertion: Preoperative risk factors. Interact. Cardiovasc. Thorac. Surg. 5, 379-382 (2006).
120. Demirozu, Z. T., Etheridge, W. B., Radovancevic, R. & Frazier, O. H. Results of HeartMate II left ventricular assist device implantation on renal function in patients requiring post-implant renal replacement therapy. J. Heart Lung Transplant. 30, 182-187 (2011).
121. Russell, S. D. et al. Renal and hepatic function improve in advanced heart failure patients during continuous-flow support with the HeartMate II left ventricular assist device. Circulation 120, 2352-2357 (2009).
122. Sandner, S. E. et al. Renal function after implantation of continuous versus pulsatile flow left ventricular assist devices. J. Heart Lung Transplant. 27, 469-473 (2008).
123. Singh, M. et al. Impact of renal function before mechanical circulatory support on posttransplant renal outcomes. Ann. Thorac. Surg. 91, 1348-1354 (2011).
124. Besarab, A. et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N. Engl. J. Med. 339, 584-590 (1998).
125. Besarab, A., Goodkin, D. A. & Nissenson, A. R. The normal hematocrit study - follow up. N. Engl. J. Med. 358, 433-434 (2008).
126. Drüeke, T. B. et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N. Engl. J. Med. 355, 2071-2084 (2006).
127. Singh, A. K. et al. Correction of anemia with epoetin alfa in chronic kidney disease. N. Engl. J. Med. 355, 2085-2098 (2006).
128. Ghali, J. K. et al. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation 117, 526-535 (2008).
129. McMurray, J. J. et al. Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): A phase III, anaemia correction, morbidity-mortality trial. Eur. J. Heart Fail. 11, 795-801 (2009).
130. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/results/NCT00358215 (2012).
131. Okonko, D. O. et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: A randomized, controlled, observer-blinded trial. J. Am. Coll. Cardiol. 51, 103-112 (2008).
132. Kazory, A. & Ross, E. A. Anemia: The point of convergence or divergence for kidney disease and heart failure? J. Am. Coll. Cardiol. 53, 639-647 (2009).
133. Burger, D., Xenocostas, A. & Feng, Q. P. Molecular basis of cardioprotection by erythropoietin. Curr. Mol. Pharmacol. 2, 56-69 (2009).
134. Chatterjee, P. K. Pleiotropic renal actions of erythropoietin. Lancet 365, 1890-1892 (2005).
135. Pitt, B. et al. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur. Heart J. 32, 820-828 (2011).
136. Anker, S. D. et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin converting enzyme inhibitors: An observational study. Lancet 361, 1077-1083 (2003).
137. Schellenbaum, G. D. et al. Weight loss, muscle strength, and angiotensin-converting enzyme inhibitors in older adults with congestive heart failure or hypertension. J. Am. Geriatr. Soc. 53, 1996-2000 (2005).
138. Hryniewicz, K., Androne, A. S., Hudaihed, A. & Katz, S. D. Partial reversal of cachexia by beta-adrenergic receptor blocker therapy in patients with chronic heart failure. J. Card. Fail. 9, 464-468 (2003).
139. Hornig, B., Arakawa, N. & Drexler, H. Effect of ACE inhibition on endothelial dysfunction in patients with chronic heart failure. Eur. Heart J. 19, G48-G53 (1998).
140. Pergola, P. E. et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N. Engl. J. Med. 365, 327-336 (2011).
141. Reata Pharmaceuticals. Company Statement: Termination of the BEACON Trial [online], http://www.reatapharma.com/investors-media/news/news-timeline/2012/ company-statement-termination-of-beacon-trial.aspx (2012).
142. Givertz, M. M., Massie, B. M., Fields, T. K., Pearson, L. L. & Dittrich, H. C. The effects of KW 3902, an adenosine A1-receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. J. Am. Coll. Cardiol. 50, 1551-1560 (2007).
143. Gottlieb, S. S. et al. BG9719 (CVT 124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 105, 1348-1353 (2002).
144. Massie, B. M. et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N. Engl. J. Med. 363, 1419-1428 (2010).
145. Bodyak, N. et al. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc. Natl Acad. Sci. USA 104, 16810-16815 (2007).
146. Thadhani, R. et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: The PRIMO randomized controlled trial. JAMA 307, 674-684 (2012).
147. Hunt, S. A. et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society. Circulation 112, e154-e235 (2005).
148. Downing, J. & Balady, G. J. The role of exercise training in heart failure. J. Am. Coll. Cardiol. 58, 561-569 (2011).
149. Heiwe, S. & Jacobson, S. H. Exercise training for adults with chronic kidney disease. Cochrane Database of Systematic Reviews, Issue 10. Art. No.: CD003236. http://dx.doi.org/10.1002/14651858.CD003236.pub2.
150. Lin, Q. Q. et al. Effect of exercise training on renal function and renal aquaporin 2 expression in rats with chronic heart failure. Clin. Exp. Pharmacol. Physiol. http://dx.doi.org/10.1111/j.1440-1681.2011.05481.x.